The word randomized tells you something important about a study. It does not tell you who could predict the next assignment, who knew which treatment was being given, or how the final outcome was judged. A useful reading starts by following those decisions in order.
- Separate assignment before treatment from awareness after treatment.
- Ask who was blinded, to what information, and at which stage.
- Judge the possible influence on a particular outcome, not just a label attached to the whole trial.
Start at the recruitment desk
Imagine a fictional trial of two rehabilitation programmes. Two hundred eligible volunteers will be assigned to programme A or B. A computer has generated a random sequence, but the recruiter can see the next allocation. If the recruiter delays enrolling someone with a difficult recovery until programme A comes up, assignment can become connected to prognosis.
The sequence can be random while its implementation is compromised. Allocation concealment protects the next assignment until enrolment is committed. Blinding concerns information after assignment. These are separate questions in Cochrane and CONSORT guidance.
On your reading card, create two lines: “How was the sequence generated?” and “Who could know the next assignment?” An answer to the first does not fill the second.
Source 1 ↗Source 2 ↗A plausible method needs a visible description
In our fictional study, compare two reports. One says “participants were randomly allocated.” The other describes a central assignment service used only after consent and eligibility confirmation. The second gives the reader a mechanism to inspect. It still does not prove that every site followed the procedure.
Try writing a timeline: consent, eligibility confirmation, assignment request, allocation revealed, treatment started. Put a question mark wherever the report leaves the order unclear. A supplement or protocol may supply the missing step. If none is available, record “not reported” instead of filling the gap with an assumption.
This exercise does not produce a numerical quality score. It identifies the specific information needed to understand recruitment.
Replace double-blind with a list of people
After assignment, ask separately about participants, care providers, outcome assessors and analysts. In a rehabilitation comparison, people may know which exercises they receive. A reader can still ask whether someone assessing a recorded walking test was unaware of group assignment.
Now give the fictional trial two outcomes: a participant’s pain rating and a laboratory measurement processed under coded identifiers. Knowledge of assignment could influence these measurements through different routes. One blanket description of blinding hides that distinction.
CONSORT asks reports to identify who was blinded and explain how. Use that as a prompt to draw your own information map: who knew the treatment, who collected the outcome, and who decided which result counted.
Source 2 ↗Read baseline differences without turning them into a verdict
Suppose programme A starts with 58 people above age 60 and programme B with 49. This invented imbalance does not itself show misconduct or failed randomization. A random process need not make every characteristic identical in a particular sample.
Ask instead whether the assignment method was credible, whether the pattern suggests something beyond ordinary chance, and whether the analysis accounted for important prognostic characteristics as planned. Do not select whichever baseline difference offers a convenient explanation after seeing the result.
Your note might say: “The age balance differs; the report describes concealed assignment; I need the planned adjusted analysis.” That is more informative than declaring the groups either perfectly matched or incomparable.
Source 1 ↗Connect the design to the claim you want to make
Imagine that the programmes differ not only in exercises but also in appointment frequency. If the trial deliberately compares these complete packages, extra contact is part of the intervention being tested. If the headline claims that one exercise alone produced the benefit, the description has become narrower than the comparison.
Write down what each group actually received. Then compare that sentence with the headline. Our reading method is to underline any ingredient present in the trial but missing from the headline: equipment, staff support, reminders or additional treatment.
When you compare this trial with another, repeat the exercise. Two trials with the same programme name may deliver quite different packages.
What would make the next report more useful?
For our fictional rehabilitation trial, a stronger report would make the assignment process inspectable, list the people who knew allocation, and explain outcome collection. It would also show participant flow and describe departures from the planned programmes.
These are questions for a future report, not findings that the programmes work. A replication could test a similar intervention in a different service, while a methods study could investigate whether assessment changed when allocation was visible. Those contributions should have different labels in a connected evidence article.
Before moving on, finish one sentence: “For this outcome, the main unresolved design question is…” Keeping the question specific prevents a prestigious design label from ending the appraisal.
Three protections, three different questions
| Stage | Question for the report | Fictional failure to investigate |
|---|---|---|
| Sequence generation | Was assignment genuinely unpredictable? | An alternating A/B schedule described as random |
| Allocation concealment | Could anyone predict the next assignment before enrolment? | A recruiter can read the allocation list |
| Blinding after assignment | Who knew the treatment while delivering or measuring it? | An assessor receives group labels with the videos |
| Outcome-specific appraisal | Could that knowledge affect this particular result? | A pain rating and a coded laboratory result treated as interchangeable |
Original educational comparison; not a clinical dataset.
Your questions, answered
Does randomization make the groups identical?
No. It protects the assignment process from systematic selection when properly implemented; chance imbalances can remain in a particular trial. Inspect the method and the pattern rather than requiring every baseline number to match.
Is allocation concealment another name for blinding?
No. Concealment concerns knowledge of the next assignment before and until allocation. Blinding concerns awareness after assignment. A report can describe one clearly while leaving the other uncertain.
Is an open-label trial automatically useless?
No. Ask which outcomes could be influenced, how they were collected, and what safeguards were feasible. An unblinded comparison may still answer an important question; the remaining uncertainties need an explicit account.
What if the abstract only says double-blind?
Check the methods and supplement for the actual people and procedures. If the information remains unavailable, say so. The phrase alone is not enough to reconstruct who knew which treatment was given.
Can a placebo solve every design problem?
No. A matching placebo can help conceal treatment identity, but it does not by itself resolve missing outcomes, selective reporting, a poorly chosen comparison or an intervention delivered differently from the plan.
How should I connect this with another trial?
Compare the assignment safeguards, treatment packages, outcome definitions and follow-up. Similar headlines do not guarantee similar experiments. The connected guides on missing data and intention-to-treat analysis cover what can happen after assignment.
Limits of this interpretation
- This is a selected educational explanation, not a systematic review, validated appraisal instrument or personal care recommendation.
- Numerical examples are hypothetical. Their deliberately simplified assumptions must not be transferred to a real study without checking its methods.
- An AI source check can miss errors; source access and the absence of independent human review are stated explicitly.
Sources & transparency
- Cochrane Handbook, chapter 8: Assessing risk of bias in a randomized trial
Public HTML, selected sections on randomization, concealment, blinding and missing outcomes; checked by AI. This guide is not a formal RoB 2 assessment. · Accessed 27 Sep 2026
- CONSORT 2025 explanation and elaboration
Publisher-indexed passages on allocation concealment, blinding and missing data checked by AI. Direct full-text and PDF retrieval returned an access error; full-paper review is not claimed. · Accessed 27 Sep 2026
Prepared and source-checked with AI on 27 September 2026. Press-news Team is the publication’s collective byline, not a claim of medical credentials or human review. No human editorial or clinical review has taken place. Source access is described below each reference. Worked examples are invented for education and do not report a clinical trial or predict an individual outcome.
Source check: AI source check — selected methods references and worked examples
Clinical review: No human editorial or clinical review
Suggest a correction